Cellectar Biosciences Inc (NASDAQ: CLRB) on Friday, soared 3.84% from the previous trading day, before settling in for the closing price of $4.69. Within the past 52 weeks, CLRB’s price has moved between $4.11 and $68.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 40.27% over the past five years. The company achieved an average annual earnings per share of 66.91%. With a float of $2.96 million, this company’s outstanding shares have now reached $3.19 million.
Cellectar Biosciences Inc (CLRB) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cellectar Biosciences Inc is 7.26%, while institutional ownership is 3.50%. The most recent insider transaction that took place on Jul 02 ’25, was worth 49,900. In this transaction Chief Executive Officer of this company bought 10,000 shares at a rate of $4.99, taking the stock ownership to the 11,638 shares. Before that another transaction happened on Jul 02 ’25, when Company’s Chief Operating Officer bought 10,000 for $4.99, making the entire transaction worth $49,900. This insider now owns 12,768 shares in total.
Cellectar Biosciences Inc (CLRB) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -11.1 earnings per share (EPS) for the period topping the consensus outlook (set at -11.2) by 0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -2.53 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 66.91% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 44.51% during the next five years compared to 40.27% growth over the previous five years of trading.
Cellectar Biosciences Inc (NASDAQ: CLRB) Trading Performance Indicators
Cellectar Biosciences Inc (CLRB) is currently performing well based on its current performance indicators. A quick ratio of 2.15 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -20.40, a number that is poised to hit -2.53 in the next quarter and is forecasted to reach -9.08 in one year’s time.
Technical Analysis of Cellectar Biosciences Inc (CLRB)
Cellectar Biosciences Inc (NASDAQ: CLRB) saw its 5-day average volume 0.13 million, a negative change from its year-to-date volume of 0.22 million. As of the previous 9 days, the stock’s Stochastic %D was 57.65%.
During the past 100 days, Cellectar Biosciences Inc’s (CLRB) raw stochastic average was set at 4.61%, which indicates a significant decrease from 64.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.40 in the past 14 days, which was lower than the 0.76 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.30, while its 200-day Moving Average is $12.19. Nevertheless, the first resistance level for the watch stands at $5.08 in the near term. At $5.30, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.62. If the price goes on to break the first support level at $4.54, it is likely to go to the next support level at $4.22. The third support level lies at $4.00 if the price breaches the second support level.
Cellectar Biosciences Inc (NASDAQ: CLRB) Key Stats
Market capitalization of the company is 15.55 million based on 3,192K outstanding shares. Right now, sales total 0 K and income totals -44,580 K. The company made 0 K in profit during its latest quarter, and -5,450 K in sales during its previous quarter.
